Side effects of alpha-interferon theraphy and impact on health-related quality of life in children with chronic viral hepatitis

Pediatric Infectious Disease Journal

Volumn 16, Issue 10, 1997, Pages 984-990

  Iorio, Raffaele ^a   Pensati, Pasqualina ^b   Botta, Salvatore ^b   Moschella, Sabino ^b   Impagliazzo, Nicola ^b   Vajro, Pietro ^b   Vegnente, Angela ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

Alpha interferon; Chronic viral hepatitis; Quality of life

Indexed keywords

ALPHA INTERFERON;

ADOLESCENT; ALOPECIA; ARTICLE; ASTHENIA; CHILD; CHRONIC HEPATITIS; DRUG EFFECT; DRUG EFFICACY; EPISTAXIS; FEBRILE CONVULSION; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; QUALITY OF LIFE; SICKNESS IMPACT PROFILE;

EID: 0030826976     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199710000-00016     Document Type: Article

References (30)

1. Di Bisceglie AM. Interferon therapy for chronic viral hepatitis (Editorial). N Engl J Med 1994;330:137-8.
2. Gregorio GV, Jara P, Hierro L, et al. Lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996;23:700-7.
3. Iorio R, Porzio S, Pensati P, Fariello I, Guida S, Vegnente A. Lymphoblastoid alpha-interferon therapy in chronic hepatitis C. Arch Dis Child 1996;74:152-6.
4. Bortolotti F, Giacchino R, Vajro P, et al. Recombinant interferon-alpha therapy in children with chronic hepatitis C. Hepatology 1995;22:1623-6.
5. Barbera C, Bortolotti F, Crivellaro C, et al. Recombinant interferon alpha-2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994;20:287-90.
6. Sokal EM, Wirth S, Goyens P, Depreterre A, Cornu C. Interferon alpha-2b therapy in children with chronic hepatitis. Gut 1993;S87-90.
7. Vajro P, Tedesco M, Fontanella A, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996;15:223-30.
8. Lai CL, Lin HJ, Yeoh EK, Lok ASF, Wu PC, Yeung CY. Placebo-controlled trial of recombinant alpha-2 interferon in Chinese HBsAg-carrier children. Lancet 1987;2:877-80.
9. Lai CL, Lin HJ, Lau JYN, et al. Effect of recombinant alpha-2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991;78:155-63.
10. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994;10:115-50.
11. Gregorio GV, Jones H, Choudhuri K, et al. Autoantibody prevalence in chronic hepatitis B virus infection: effect of interferon alpha. Hepatology 1996;24:520-3.
12. Spiegel RJ, Intron A (interferon alfa-2b): clinical overview and future directions. Semin Oncol 1986;13:89-101.
13. Bergner M, Bobbitt RA, Pollard W, Martin MA, Gilson BS. The Sickness Impact Profile: validation of health status measure. Med Care 1976;14:57-67.
14. MacKenzie CR, Charlson ME, Di Gioia D, Kelley K. Can the Sickness Impact Profile measure change? An example of scale assessment. J Chron Dis 1986;39:429-38.
15. De Bruin AF, De Witte LP, Stevens F, Diederiks JPM. Sickness Impact Profile: the state of the art of a generic functional status measure. Soc Sci Med 1992;35:1003-14.
16. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
17. Ruiz-Moreno M, Jimenez J, Porres JC, Bartolome J, Moreno A, Carreno A. A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990;45:26-33.
18. Utili R, Sagnelli E, Galanti B, et al. Prolonged treatment of children with chronic hepatitis B with recombinant alpha-2a interferon: a controlled, randomized study. Am J Gastroenterol 1991;86:327-30.
19. Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991;13:1035-9.
20. Bruguera M, Amat L, Garcia O, et al. Treatment of chronic hepatitis B in children with recombinant alpha-interferon. J Clin Gastroenterol 1983;17:296-9.
21. Utili R, Sagnelli E, Gaeta GB, et al. Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study. J Hepatol 1994; 20:163-7.
22. Ruiz-Moreno M, Rua MJ, Castillo I, et al. Treatment of children with chronic hepatitis C with recombinant interferon-alpha: a pilot study. Hepatology 1992;16:882-5.
23. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-10.
24. Hsu HY, Chang MH, Lee CY, Chen JS, Hsu HC, Chen DS. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology 1992;15:382-6.
25. Bortolotti F, Vajro P, Cadrobbi P, et al. Cryptogenic chronic liver disease and hepatitis C virus infection in children. J Hepatol 1992;15:73-6.
26. Iorio R, Guida S, Porzio S, Fariello I, Vegnente A. Chronic non-A, non-B hepatitis: role of hepatitis C virus. Arch Dis Child 1993;68:219-22.
27. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economical appraisal. Hepatology 1995;22:1863-73.
28. Koff RS, Seefs LB. Economic modeling of treatment in chronic hepatitis B and chronic hepatitis C: promises and limitations. Hepatology 1995;22:1880-2.
29. Black M, Peters M. Alpha interferon treatment in chronic hepatitis C: need for accurate diagnosis in selecting patients. Ann Intern Med 1992;116:86-8.
30. Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994;16:334-3.